Skip to main content

Development of new therapeutic substances and strategies for treatment of pain in patients with advanced stages of cancer

Objective

Prolonging the life expectations of patients with progressive cancer could be done by modern medicine. However progressive pain that is associated with progression of disease is the major factor that destructs last moment of life. Severe and progressive and uncontrolled pain is a major reason of requesting euthanasia. The applications of oral (morphine) pills or transdermal patches with lipophylic analgesic drugs are the most common treatments of cancer pain. These compounds penetrating into central nervous system produce side effects (respiratory depression, constipation, tolerance, sedation, etc) to such extend that pain treatment is reduced by the doctor or refused by the patients. The discoveries of the last years indicated the changes in expressions of pro- and antynociceptive receptors in pathologically changed peripheral tissues as well as in central nervous system. The modulation of these receptors with composition of receptor ligands may block nociceptive signal formation and transmission more effectively than traditional monotherapies. The objectives of this project is to focus on development of new multitarget compounds and the method which will interact in large proportion with opioid receptors expressed in inflamed and/or pathologically modified tissues. Partial penetration into central nervous system will results in synergic pain suppression interaction between peripheral and central nervous system. Alternatively, developed compounds could be applied directly into central nervous system to interact with specific, pathological composition of receptors. Developed compounds will be screened in vitro in a cell silicon hybrid biosensor and selected compounds, in vivo in rodent's cancer pain models. Project wills results with new basic data on structural requirements of analgesics for treatment of persistent cancer pain in advances stages and develops new compounds characterized to the stage that allow to promote them for further clinical phase'.

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

MEDICAL RESEARCH CENTRE POLISH ACADEMY OF SCIENCES (INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ IM. M. MOSSAKOWSKIEGO POLSKIEJ AKADEMII NAUK)
Address
Pawinskiego Street 5
Warsaw
Poland

Participants (10)

UNIVERSITY OF CATANIA
Italy
Address
Piazza Universita, 2
Catania
VRIJE UNIVERSITEIT BRUSSEL
Belgium
Address
Pleinlaan 2
Brussels
WARSAW UNIVERSITY
Poland
Address
Krakowskie Przedmiescie 26/28
Warsaw
BIOLOGICAL RESEARCH CENTRE, HUNGARIAN ACADEMY OF SCIENCES
Hungary
Address
Temesvari Krt. 62
521 Szeged
NATIONAL CENTRE FOR SCIENTIFIC RESEARCH "DEMOKRITOS"
Greece
Address
Patriarchou-gregoriou & Neapoleos, Ag. Paraskevi-attikis
60228 Athens
INSTITUTE OF ORGANIC CHEMISTRY, POLISH ACADEMY OF SCIENCES
Poland
Address
Kasprzaka Street 44/52
Warsaw
INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE
Poland
Address
Rydygiera Street 8
Warsaw
UNIVERSITY OF ROSTOCK
Germany
Address
Albert-einstein-str. 3
Rostock
DR. SCHRÖDER PATTERN EXPERT
Germany
Address
Heinrich-heine-str. 12
Borsdorf
STEINBEIS FORSCHUNGSZENTREN GMBH
Germany
Address
Willi-bleicher-str. 19
Stuttgart